Jitendra Pariyar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jitendra Pariyar has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Afrin Fatima Shaffi
Moi Teaching Referral Hospital, Kenya
1 shared publication Aisha Mustapha
Ahmadu Bello University Teaching Hospital, Zaria, Nigeria
1 shared publication- Anamika Maharjan
Nepal Fertility Care Center (NFCC), Gusingal, Sanepa, Lalitpur 44600, Nepal
1 shared publication Anmol Bajwa
World Ovarian Cancer Coalition, Toronto, Canada
1 shared publicationAnupama Bhattarai
Paropakar Maternity and Women’s Hospital, National Academy of Medical Sciences, Kathmandu
1 shared publication- Archana Amatya
Nick Simons Institute
1 shared publication
Latest Publications
- Open Access
- 5 September 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (9) , 539
Community-Based HPV Self-Sampling to Enhance Access to Cervical Cancer Prevention: A Continuum-of-Care Model from Urban Nepal
Cervical cancer remains the leading cause of cancer-related mortality among women in Nepal, where national screening coverage is approximately 16%. This study evaluated the feasibility of a community-based, door-to-door self-sampling strategy for high-risk human papillomavirus (hrHPV) detection in an urban municipality of central Nepal and assessed hrHPV prevalence, genotype distribution, screening outcomes, and associated demographic factors. A cross-sectional study was conducted between September 2023 and May 2024 in Ward No. 3 of Lalitpur Metropolitan City. Women aged 30–60 years were recruited through trained community health workers, provided education and home-based self-sampling kits, and completed a demographic questionnaire. Dry cervical swabs from 418 participants were tested for hrHPV. Women with positive results underwent visual inspection with acetic acid (VIA), followed by colposcopy, biopsy when indicated, and thermal ablation for confirmed precancerous lesions. Overall participation was 64.1%, and hrHPV prevalence was 10.3%. Non-16/18 hrHPV genotypes predominated (55.8%), followed by HPV16 (20.9%). Women aged > 50 years were more likely to be hrHPV- and VIA-positive (OR = 7.39, p = 0.02). Six pre-cancer cases were identified: five cervical intraepithelial neoplasia (CIN1) and one CIN3 case. Community-based hrHPV self-sampling was found to be feasible and achieved effective linkage to triage and treatment, supporting its consideration for strengthening cervical cancer screening in Nepal.
- 5 September 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (9) , 539
Open AccessCommunity-Based HPV Self-Sampling to Enhance Access to Cervical Cancer Prevention: A Continuum-of-Care Model from Urban Nepal
Cervical cancer remains the leading cause of cancer-related mortality among women in Nepal, where national screening coverage is approximately 16%. This study evaluated the feasibility of a community-based, door-to-door self-sampling strategy for high-risk human papillomavirus (hrHPV) detection in an urban municipality of central Nepal and assessed hrHPV prevalence, genotype distribution, screening outcomes, and associated demographic factors. A cross-sectional study was conducted between September 2023 and May 2024 in Ward No. 3 of Lalitpur Metropolitan City. Women aged 30–60 years were recruited through trained community health workers, provided education and home-based self-sampling kits, and completed a demographic questionnaire. Dry cervical swabs from 418 participants were tested for hrHPV. Women with positive results underwent visual inspection with acetic acid (VIA), followed by colposcopy, biopsy when indicated, and thermal ablation for confirmed precancerous lesions. Overall participation was 64.1%, and hrHPV prevalence was 10.3%. Non-16/18 hrHPV genotypes predominated (55.8%), followed by HPV16 (20.9%). Women aged > 50 years were more likely to be hrHPV- and VIA-positive (OR = 7.39, p = 0.02). Six pre-cancer cases were identified: five cervical intraepithelial neoplasia (CIN1) and one CIN3 case. Community-based hrHPV self-sampling was found to be feasible and achieved effective linkage to triage and treatment, supporting its consideration for strengthening cervical cancer screening in Nepal.
- Open Access
- 8 April 2025
- Published by Elsevier in Journal of Cancer Policy
- Vol. 44, 100582
Challenges and opportunities in ovarian cancer care: A qualitative study of clinician perspectives from 24 low- and middle-income countries
- 8 April 2025
- Published by Elsevier in Journal of Cancer Policy
- Vol. 44, 100582
Open AccessChallenges and opportunities in ovarian cancer care: A qualitative study of clinician perspectives from 24 low- and middle-income countries
- Open Access
- 2 October 2020
- Published by Nepal Journals Online (JOL) in Nepalese Journal of Cancer
- Vol. 4 (1) , 24-27
Carcinosarcoma of the Uterus: An Elusive Diagnosis
Introduction: Carcinosarcoma or Malignant Mixed Mullerian Tumor (MMMT) of the uterus is a rare malignant tumor comprising both carcinomatous and sarcomata’s components. Worldwide it accounts for two to five percentages of all uterine malignancies. However, there is a paucity of reports in Nepalese literature. Case report: A 62 year’s postmenopausal woman with diabetes and hypertension presented with urinary symptoms for two months and passage of fleshy mass per vagina for two days. Ultrasound was inconclusive, whereas, Magnetic Resonance Imaging (MRI) showed an endo-cervical mass. Pre-operative biopsy of the masssuggested leiomyosarcoma. Abdominal hysterectomy with bilateral salpingo-oophorectomy and pelvic andpara-aortic lymphadenectomy was performed. Per-operatively, an atrophic uterus, a dimple in the funds, andballooning of the lower uterine segment and vagina were noted. The cut section showed an exophytic polypoidalmass with base in the fundus. Histopathology revealed Stage IA carcinosarcoma with aggressive mitotic figures. Immunohistochemistry confirmed the diagnosis of carcinosarcoma with a heterogonous rhabdomyosarcomatouscomponent. Adjuvant chemotherapy and radiation therapy was advised. Conclusion: The preoperative diagnosis of carcinosarcoma or MMMT was difficult and might be missed on biopsy as well. Owing to its aggressive nature and higher rates of post-surgical recurrence, carcinosarcoma accounts for around one-fifth of deaths due to uterine malignancies. Surgery is the primary treatment modality, yet much study is needed before evidence-based adjuvant management for improving its outcome is established.
- 2 October 2020
- Published by Nepal Journals Online (JOL) in Nepalese Journal of Cancer
- Vol. 4 (1) , 24-27
Open AccessCarcinosarcoma of the Uterus: An Elusive Diagnosis
Introduction: Carcinosarcoma or Malignant Mixed Mullerian Tumor (MMMT) of the uterus is a rare malignant tumor comprising both carcinomatous and sarcomata’s components. Worldwide it accounts for two to five percentages of all uterine malignancies. However, there is a paucity of reports in Nepalese literature. Case report: A 62 year’s postmenopausal woman with diabetes and hypertension presented with urinary symptoms for two months and passage of fleshy mass per vagina for two days. Ultrasound was inconclusive, whereas, Magnetic Resonance Imaging (MRI) showed an endo-cervical mass. Pre-operative biopsy of the masssuggested leiomyosarcoma. Abdominal hysterectomy with bilateral salpingo-oophorectomy and pelvic andpara-aortic lymphadenectomy was performed. Per-operatively, an atrophic uterus, a dimple in the funds, andballooning of the lower uterine segment and vagina were noted. The cut section showed an exophytic polypoidalmass with base in the fundus. Histopathology revealed Stage IA carcinosarcoma with aggressive mitotic figures. Immunohistochemistry confirmed the diagnosis of carcinosarcoma with a heterogonous rhabdomyosarcomatouscomponent. Adjuvant chemotherapy and radiation therapy was advised. Conclusion: The preoperative diagnosis of carcinosarcoma or MMMT was difficult and might be missed on biopsy as well. Owing to its aggressive nature and higher rates of post-surgical recurrence, carcinosarcoma accounts for around one-fifth of deaths due to uterine malignancies. Surgery is the primary treatment modality, yet much study is needed before evidence-based adjuvant management for improving its outcome is established.
- 5 September 2019
- Published by Morressier GmbH
Carcinoma of vulva, case series
Title: Carcinoma of vulva, case series. Saujanya Karmacharya1, Jitendra Pariyar1, Sameer Neupane2, Srijana Koirala2, Asima Mukhopadhyay1. 1Gynecologic Oncology Unit, Civil Service Hospital, Kathmandu, Nepal. 2Department of Pathology, Civil Service Hospital, Kathmandu, Nepal. Correspondence: Dr. Jitendra Pariyar, Department of Gynecology and Obstetrics, Civil Service Hospital,
- 5 September 2019
- Published by Morressier GmbH
Carcinoma of vulva, case series
Title: Carcinoma of vulva, case series. Saujanya Karmacharya1, Jitendra Pariyar1, Sameer Neupane2, Srijana Koirala2, Asima Mukhopadhyay1. 1Gynecologic Oncology Unit, Civil Service Hospital, Kathmandu, Nepal. 2Department of Pathology, Civil Service Hospital, Kathmandu, Nepal. Correspondence: Dr. Jitendra Pariyar, Department of Gynecology and Obstetrics, Civil Service Hospital,
- Open Access
- 17 February 2014
- Published by Springer Nature in BMC Women's Health
- Vol. 14 (1) , 29
Estimates of delays in diagnosis of cervical cancer in Nepal
Cervical cancer is the leading cause of cancer related deaths among women in Nepal. The long symptom to diagnosis interval means that women have advanced disease at presentation. The aim of this study was to identify, estimate and describe the extent of different delays in diagnosis of cervical cancer in Nepal.
- 17 February 2014
- Published by Springer Nature in BMC Women's Health
- Vol. 14 (1) , 29
Open AccessEstimates of delays in diagnosis of cervical cancer in Nepal
Cervical cancer is the leading cause of cancer related deaths among women in Nepal. The long symptom to diagnosis interval means that women have advanced disease at presentation. The aim of this study was to identify, estimate and describe the extent of different delays in diagnosis of cervical cancer in Nepal.